ALX Oncology Holdings Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ALX Oncology Holdings Inc. (ALXO) on January 16, 2025, with the earliest event reported on that date. The filing discloses significant changes to the Company's executive leadership and Board of Directors.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel appointments and compensation arrangements.
Material Changes
- Appointment of Chief Financial Officer: Harish Shantharam was appointed CFO, effective January 21, 2025, replacing Shelly Pinto. Ms. Pinto will remain as Senior Vice President, Finance and Chief Accounting Officer.
- Appointment of Directors: The Board size increased to six members with the appointment of Barbara Klencke, M.D. (Class II) and Chris Takimoto, M.D., Ph.D. (Class III), effective January 18, 2025.
- Committee Restructuring: The Board reconstituted its committees, including the creation of a new Research and Development Committee. Dr. Klencke joined the Audit and R&D Committees, while Dr. Takimoto joined the Compensation and R&D Committees.
Compensation and Governance Details
- CFO Compensation: Mr. Shantharam's annual base salary is $490,000 with a target cash bonus of 40%. He received a stock option to purchase 600,000 shares under the 2025 Inducement Equity Incentive Plan, vesting 25% after one year and monthly thereafter.
- Director Compensation: Dr. Klencke and Dr. Takimoto each received an initial stock option award for 40,400 shares, vesting monthly over 36 months. They are also eligible for annual cash compensation and equity awards per the outside director policy.
- Independence: The Board determined both new directors qualify as independent under SEC and Nasdaq standards.
Investor Verification Checklist
- Verify the effective dates of the CFO transition and Board appointments (January 18 and 21, 2025).
- Review the full text of the employment offer letter for Mr. Shantharam, which the Company intends to file as an exhibit to a subsequent periodic report.
- Confirm the vesting schedules for the 600,000 CFO stock options and the 40,400 director stock options.
- Monitor the composition of the newly constituted Research and Development Committee.